Five-Year Patterns of Diabetic Retinopathy Progression in US Clinical Practice

Purpose To characterize the natural course of diabetic retinopathy (DR) in contemporary clinical practice. Patients and Methods This was a retrospective analysis of US claims data collected between January 1, 2006, and April 30, 2017. Patients aged ≥18 years with continuous medical and prescription insurance coverage for 18 months before DR diagnosis (index date) and for a follow-up period of 5 years were included (N=14,490). The time and risk of progressing to severe nonproliferative DR (NPDR) or proliferative DR (PDR) and of developing diabetic macular edema (DME) were evaluated over 5 years in patients stratified by DR severity at initial diagnosis. Results The estimated probability of progressing to severe NPDR or PDR within 5 years of diagnosis was 17.6% for patients with moderate NPDR versus 5.8% for mild NPDR. The probability of developing DME within 5 years was 62.6%, 44.6%, and 28.4% for patients diagnosed with severe NPDR, moderate NPDR, and PDR, respectively, versus 15.6% for mild NPDR. Among those observed to progress, median time to severe NPDR or PDR was approximately 2.0 years in patients with moderate NPDR, whereas median time to DME was approximately 0.5 years in patients with severe NPDR, 1.3 years in moderate NPDR, and 1.6 years in PDR. Relative to mild NPDR, adjusted hazard ratios (95% confidence interval) for progression to severe NPDR or PDR within 5 years were 3.12 (2.61–3.72) in patients with moderate NPDR, and for incident DME were 5.92 (5.13–6.82), 3.54 (3.22–3.91), and 1.96 (1.80–2.14) in patients with severe NPDR, moderate NPDR, and PDR, respectively. Conclusion The risk of DR progression and DME over 5 years was highest among patients diagnosed with moderate and severe NPDR, respectively. Our findings reinforce the importance of close monitoring for these patients to avoid unobserved disease progression toward PDR and/or DME.

[1]  Jennifer I. Lim,et al.  Diabetic Retinopathy Preferred Practice Pattern®. , 2019, Ophthalmology.

[2]  P. Mitchell,et al.  Evaluating the Impact of Intravitreal Aflibercept on Diabetic Retinopathy Progression in the VIVID-DME and VISTA-DME Studies. , 2018, Ophthalmology. Retina.

[3]  D. Roth,et al.  Ranibizumab Induces Regression of Diabetic Retinopathy in Most Patients at High Risk of Progression to Proliferative Diabetic Retinopathy. , 2018, Ophthalmology. Retina.

[4]  Fitriani Fitriani,et al.  THE PREVALENCE OF DIABETIC RETINOPATHY , 2018 .

[5]  Z. Haskova,et al.  Vision-Related Functional Burden of Diabetic Retinopathy Across Severity Levels in the United States , 2017, JAMA ophthalmology.

[6]  W. Glasheen,et al.  Diabetes Complications Severity Index (DCSI)-Update and ICD-10 translation. , 2017, Journal of diabetes and its complications.

[7]  Jennifer K. Sun,et al.  Diabetic Retinopathy: A Position Statement by the American Diabetes Association , 2017, Diabetes Care.

[8]  Gretchen A. Stevens,et al.  Causes of vision loss worldwide, 1990-2010: a systematic analysis. , 2013, The Lancet. Global health.

[9]  T. Gardner,et al.  Predicting Development of Proliferative Diabetic Retinopathy , 2013, Diabetes Care.

[10]  J. Ehrlich,et al.  Long-term effects of ranibizumab on diabetic retinopathy severity and progression. , 2012, Archives of ophthalmology.

[11]  B. Klein,et al.  Global Prevalence and Major Risk Factors of Diabetic Retinopathy , 2012, Diabetes Care.

[12]  Roberta McKean-Cowdin,et al.  Severity of diabetic retinopathy and health-related quality of life: the Los Angeles Latino Eye Study. , 2011, Ophthalmology.

[13]  Ann L. Albright,et al.  Prevalence of diabetic retinopathy in the United States, 2005-2008. , 2010, JAMA.

[14]  R. Klein,et al.  Four-year incidence and progression of diabetic retinopathy and macular edema: the Los Angeles Latino Eye Study. , 2010, American journal of ophthalmology.

[15]  R. Klein,et al.  Rates of Progression in Diabetic Retinopathy During Different Time Periods , 2009, Diabetes Care.

[16]  Ronald Klein,et al.  The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. , 2008, Ophthalmology.

[17]  Barbara Eden Kobrin Klein Overview of Epidemiologic Studies of Diabetic Retinopathy , 2007 .

[18]  Nathan Congdon,et al.  The Prevalence of Diabetic Retinopathy in the United States , 2002 .

[19]  Stephen J. Aldington,et al.  UKPDS 50: Risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis , 2001, Diabetologia.

[20]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[21]  D L DeMets,et al.  The Wisconsin Epidemiologic Study of Diabetic Retinopathy. IX. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years. , 1989, Archives of ophthalmology.

[22]  D L DeMets,et al.  The Wisconsin Epidemiologic Study of Diabetic Retinopathy. X. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is 30 years or more. , 1989, Archives of ophthalmology.

[23]  C. Steiner,et al.  Comorbidity measures for use with administrative data. , 1998, Medical care.

[24]  Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. , 1991, Ophthalmology.